microRNA
11
4
4
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (11)
The Difference of microRNA and Circulating Tumor Cells in Blood Among Cancer Patients With Immunotherapy
Dual-Task Exercise for Mild Traumatic Brain Injury (mTBI)
Trial to Evaluate the Clinical Utility of Non-invasive Endometrial Receptivity Test (Ora) in Patients With Implantation Failure
Effect of Exercise on MiR-126 in Individuals With Prediabetes
The Application of DNA Nanomachines for Detecting microRNA in Blood for the Diagnosis of Pancreatic Cancer. Diagnosis of Pancreatic Cancer
Human Gut Microbiota and microRNA Expression
microRNA in Thyroid Cancer
Pan-Cardio-Genetics Clot Assessment in Acute Coronary Syndromes
Coronary Artery Calcification in Type 2 Diabetes Mellitus (USCAC Study)
The Potential Role Of MicroRNA-155 And Telomerase Reverse Transcriptase In Diagnosis Of Non-Muscle Invasive Bladder Cancer And Their Pathological Correlation
Circulating microRNAs in Patients With STEMI Complicated With Cardiogenic Shock